Breaking News, Collaborations & Alliances

Vyripharm and Regis Sign Off on a Master Drug Program Agreement

For expediting cGMP manufacture of antiviral agents for diagnostic evaluation of COVID-19

By: Contract Pharma

Contract Pharma Staff

Vyripharm Biopharmaceuticals, a subsidiary of Vyripharm Enterprises, LLC, located in the Texas Medical Center in Houston, TX, has signed off on a Master Drug Program Agreement with Regis Technologies, a contract development manufacturing organization (CDMO) in Morton Grove, IL. The agreement allows Vyripharm to further develop its antiviral diagnostic agents to first-in-human studies of viral infections such as SARS, MERS and COVID-19.   With the ongoing COVID-19 pandemic, the pharmaceutical and...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters